Welcome to our dedicated page for Sonnet Biotherapeutc Hldng news (Ticker: SONN), a resource for investors and traders seeking the latest updates and insights on Sonnet Biotherapeutc Hldng stock.
Sonnet BioTherapeutics Holdings Inc (NASDAQ: SONN) is a clinical-stage biotechnology innovator developing targeted immunotherapies through its proprietary FHAB platform. This page serves as the definitive source for verified company announcements, including clinical trial updates, regulatory milestones, and strategic developments in immuno-oncology.
Investors and researchers will find timely updates on SONN's pipeline progress, including its lead candidates targeting cancer and immune-mediated conditions. Our curated news collection features press releases about FHAB technology advancements, partnership announcements, and financial disclosures – all essential for tracking this innovative biotech's trajectory.
The repository systematically organizes updates across key categories: new patent filings, preclinical data publications, Phase 1 trial results, and executive team developments. Each entry maintains strict editorial standards to ensure compliance with financial reporting regulations.
For those monitoring advancements in bispecific antibody therapies and tumor microenvironment modulation, this resource offers structured access to SONN's scientific and corporate developments. Bookmark this page for efficient tracking of how the company's platform-based approach translates to clinical progress and strategic positioning within the competitive oncology landscape.
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) has rescheduled its annual stockholders meeting to July 15, 2021, at 9:00 a.m. Eastern Time, to be conducted virtually. The meeting will include discussions on key proposals such as the election of directors and appointment of the independent auditing firm for the fiscal year ending September 30, 2021.
Sonnet is focused on developing innovative biologic drugs using its proprietary FHAB technology, which enhances drug efficacy through targeted delivery mechanisms.
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) announced the issuance of U.S. Patent No. 11,028,166 for its Fully Human Albumin Binding (FHAB™) technology, valid until March 2039. This patent protects therapeutic fusion proteins designed for tumor targeting and extended pharmacokinetics. CEO Pankaj Mohan emphasized its significance in differentiating from competitors and validating their product pipeline.
Sonnet's FHAB platform enhances penetration and retention in tumors, showcasing potential for improved efficacy against wild type cytokines.
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) announced positive results from a preclinical GLP repeat-dose study of SON-1010, a proprietary Interleukin 12 biologic, in nonhuman primates. The No Observed Adverse Event Level was over 50 times the expected human dose, with no cytokine release syndrome noted. The pharmacokinetic profile showed a half-life of approximately 40 hours, enhancing therapeutic potential. Additionally, significant increases in Interferon-γ, an anti-tumor cytokine, were recorded. These findings support the safety and efficacy of SON-1010 for future clinical trials.
Sonnet BioTherapeutics Holdings (NASDAQ:SONN) has signed a licensing agreement with New Life Therapeutics (NLT) for low-dose Interleukin 6 to treat Diabetic Peripheral Neuropathy (DPN) in ASEAN countries. The deal includes an upfront payment of $1 million and up to $20 million in milestone payments, along with royalties of 12% to 30% on net sales. NLT will manage a Phase 1b/2a clinical trial, set to begin in the second half of 2021. This partnership aims to address rising diabetes rates in the region and bring innovation to neuropathy treatment.
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) provided an update on its ongoing programs. The company has completed GLP toxicity studies for SON-1010 and SON-080, with plans to initiate clinical trials in the second half of 2021. A partnership with New Life Therapeutics for SON-081 aims to advance it into clinical trials. Sonnet is actively developing several candidates, including SON-1210 and SON-2014, with IND submissions planned. Additionally, the company received a Notice of Allowance for its FHAB delivery technology patent, strengthening its intellectual property portfolio.
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) has announced the appointments of Richard Kenney, M.D. as Chief Medical Officer and Manuel Dafonseca as Head of Clinical Operations, effective March 22, 2021. Dr. Kenney, with over 20 years of experience, will lead clinical development for Sonnet’s FHAB platform, aimed at treating challenging cancers. Dafonseca brings over 30 years of expertise in pharmaceutical development, recently managing oncology clinical operations at Merck. These strategic appointments come as the company prepares to advance its proprietary IL-12 therapeutic candidate, SON-1010, into clinical trials.
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) provided a business update and financial results for Q1 FY 2021, reporting a cash balance of $2.3 million as of December 31, 2020. The company announced successful non-human primate studies for its lead therapeutic candidate, SON-1010, which demonstrated on-target activity and tolerability. Sonnet plans to file an IND for SON-1010 in the second half of 2021, alongside additional trials for SON-080 and SON-1210. The company has initiated an at-the-market offering program aiming to raise up to $15.9 million.
Sonnet BioTherapeutics (NASDAQ:SONN) has completed a successful non-human primate study of SON-1010, a fully human Interleukin 12 (IL-12) therapeutic candidate. The study demonstrated SON-1010's improved pharmacokinetic profile compared to recombinant human IL-12 and confirmed its safety at doses significantly higher than expected for human trials. Key findings include a prolonged half-life of 40 hours for subcutaneous doses and potent pharmacodynamic effects indicated by increased Interferon-γ levels. These results pave the way for IND filing with the FDA and potential clinical trials targeting lung and head and neck cancers.
Sonnet BioTherapeutics announced positive results from a preclinical study of SON-1010, a human IL-12 candidate. The SCID mouse study showed no toxicity or adverse immune reactions, indicating a favorable safety profile. Notably, cytokine storm was absent, and the dosing demonstrated a dose-dependent response in activating the immune system. The company plans to submit an Investigational New Drug (IND) application in 2021 and aims to initiate first-in-human clinical studies in the latter half of the year, reinforcing its commitment to advancing oncology therapies.
